Cancer Research SABCS Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by zum Büschenfelde, C. M.
Right arrow Articles by Bernhard, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by zum Büschenfelde, C. M.
Right arrow Articles by Bernhard, H.
[Cancer Research 62, 2244-2247, April 15, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

Antihuman Epidermal Growth Factor Receptor 2 (HER2) Monoclonal Antibody Trastuzumab Enhances Cytolytic Activity of Class I-restricted HER2-specific T Lymphocytes Against HER2-overexpressing Tumor Cells1

Christian Meyer zum Büschenfelde, Christine Hermann, Burkhard Schmidt, Christian Peschel and Helga Bernhard2

Department of Hematology/Oncology, Klinikum rechts der Isar, Technical University of Munich, D-81675 Munich, Germany


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 
The monoclonal antibody trastuzumab (Herceptin) directed against thehuman epidermal growth factor receptor 2 (HER2) results in tumor regressions when administered to patients with HER2-overexpressing breast cancer. One of the underlying mechanisms of this antibody-induced tumor regression is based on the internalization and degradation of HER2 by tumor cells on interaction with trastuzumab, subsequently inhibiting signal transduction pathways. As antibody-induced degradation of HER2 is likely to be accompanied with increased numbers of HER2 peptides presented with MHC, we asked whether trastuzumab-treated tumor cells were more susceptible to CTL-mediated lysis. Here we show that the cytolytic activity of human, HER2-specific CD8+ CTLs is augmented by anti-HER2 antibody trastuzumab. HER2-reactive CTL clones lyse class I-matched, HER2-overexpressing tumor cells more efficiently after treatment with trastuzumab. The potentially synergistic activity of HER2-specific antibody and CTL encourages the development of an HER2-targeted immunotherapy using a combination of inhibitory antibodies and CTLs for patients with HER2-overexpressing tumors.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results and Discussion
 REFERENCES
 
HER23 represents an appealing target for humoral and cellular immunotherapy because HER2 is expressed at high levels in a variety of human cancers, such as breast cancer (1) . Overexpression of antigenic proteins, such as HER2, is coupled with a high protein turnover, leading subsequently to a high number of MHC class I peptide complexes on the cell surface (Ref. 2 ; for review, see Ref. 3 ). Therefore, HER2++ tumor cells are potentially good target cells for tumor-reactive CTLs recognizing HER2-derived peptides in context with MHC class I molecules. Indeed, HER2-specific CTLs have been isolated from normal donors and patients with HER2++ tumors (4, 5, 6, 7) . However, lytic activity of separated CTLs has been low because HER2 is a self-antigen attributable to induction of tolerance, and, therefore, HER2-specific T cells display a low avidity T-cell receptor. On this basis, we investigated whether the lytic potential of HER2-specific CTLs could be improved with the help of trastuzumab, an inhibitory antibody against HER2. On binding of anti-HER2 mAb trastuzumab, the receptor is internalized and degraded, subsequently inhibiting HER2-mediated signal transduction and tumor cell growth (8, 9, 10) . Theoretically, degradation of the internalized HER2 might increase the amount of HER2 protein available for loading into MHC class I molecules, subsequently leading to an enhanced tumor lysis by HER2-specific CTL.

Here we show that anti-HER2 mAb trastuzumab sensitizes HER2++ tumor cells to lysis by HER2-specific CTLs in vitro. HER2-reactive T-cell clones generated from healthy donors and breast cancer patients lyse class I-matched, HER2-overexpressing tumor cells more efficiently after incubation with trastuzumab. These findings encourage the further development of a combined immunotherapy with trastuzumab and autologous HER2-specific CTLs for patients with HER2-overexpressing tumors.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results and Discussion
 REFERENCES
 
Cells.
The HER2++ ovarian cancer cell line SKOV3 (HLA phenotype: A3, A28, B18, and B35) and the HER2++ breast cancer cell line SKBR3 (HLA phenotype: A11, B40, and B18) were obtained from American Type Culture Collection (Manassas, VA). The HLA-A2+ transfectant cell line SKOV3tA2 was a gift from M. L. Disis (University of Washington, Seattle, WA). SKOV3tA2 express the TfR on the cell surface as determined by fluorescence-activated cell sorting analysis (data not shown). The HLA-A2+, transporter associated with antigen processing (TAP)-deficient T2 cell line was provided by P. Cresswell (Yale University, New Haven, CT). Tumor cell lines and T2 cells were cultured in RPMI 1640 (Life Technologies, Inc., Paisley, Scotland) supplemented with 10% heat-inactivated FCS, 100 units/ml penicillin, 100 µg/ml streptomycin, and 2 mM glutamine. For down-regulation experiments, confluent SKOV3tA2 cells were cultured in the presence of 100 µg/ml anti-HER2 mAb trastuzumab (Herceptin; Roche, Grenzach-Wyhlen, Germany) or 100 µg/ml anti-CD71 mAb (clone 32001A; BD PharMingen, San Diego, CA) for 2 days.

HER2-specific, class I-restricted CTL clones were generated from different donors by repetitive stimulation with autologous DCs as described recently (6, 7) . In brief, HLA-A3-restricted CTLs FS-32 and HLA-A2-restricted CTLs PS-D10 and HR-8 were generated from different donors by repetitive stimulation with autologous stem cell-derived DCs (11) retrovirally transduced with HER2. HLA-A2-restricted CTLs NK-1 and IR-1 were established by stimulation with monocyte-derived autologous DCs pulsed with peptides known to be naturally presented with HLA-A2. HER2-specific CTLs NK-1 were generated against HER2369–377 and melan-A-reactive CTLs IR-1 against melan-A27–35. Antigen-specific T-cell lines were cloned by limiting dilution and expanded according to the method described previously by Yee et al. (12) .

Western Blot Analysis.
Cell lysates were made from SKOV3tA2 cells that were cultured in the presence or absence of anti-HER2 mAb trastuzumab or anti-CD71 mAb. Lysates from equal amounts of cells were separated by SDS-PAGE and transferred to nitrocellulose. The HER2 protein was identified using the mAb c-neu-Ab3 recognizing the intracellular domain of HER2 (Oncogene Science, Uniondale, NY) as primary Ab and rabbit antimouse peroxidase-conjugated Fab2 fragment (Amersham Pharmacia Biotech, Freiburg, Germany) as secondary Ab. The blots were developed using a chemiluminescent reaction (enhanced chemiluminescence; Amersham Pharmacia Biotech).

Cytotoxicity Assay.
Cytolytic activity was determined as described previously (6) . Briefly, 106 tumor cells were labeled in 100 µl of FCS with 100 µCi/ml 51Cr for 1 h at 37°C. T2 cells were labeled in 100 µl of FCS with 200 µCi/ml for 1.5 h at 37°C and then loaded with 10 µg/ml peptide and 3 µg/ml ß2-microglobulin (Sigma, Taufkirchen, Germany) for 1 h at room temperature. 51Cr-labeled target cells and graded doses of T cells were given in 200 µl of RPMI supplemented with 10% heat-inactivated human AB serum pooled from healthy donors. Cells were incubated for 4 h at 37°C, 100 µl of supernatant were collected, and radioactivity was measured in a gamma counter. The percentage of specific 51Cr release was calculated as follows: % specific 51Cr release = (experimental 51Cr release - spontaneous 51Cr release) x 100/(maximum 51Cr release - spontaneous 51Cr release). Maximum 51Cr release was obtained by adding 100 µl of 1% NP40 (Sigma, St. Louis, MO) to 100 µl of labeled target cells. Spontaneous 51Cr release ranged from 5 to 10% of the total counts incorporated. The data in the figures refer to the mean of two replicates. SDs were <5% of the mean. Similar results were obtained with at least three independent experiments.


   Results and Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
REFERENCES
 
Drebin et al. (8) have demonstrated that exposure of HER2-transformed cells to inhibitory anti-HER2 antibodies results in the rapid loss of both cell surface and total cellular HER2. This antibody-induced down-regulation of HER2 is a result of accelerated endocytosis and correlates with the tumor-inhibitory potential of the antibody (9) . The anti-HER2 mAb trastuzumab was engineered from a murine mAb that inhibits growth of HER2++ tumor cells via receptor internalization (13) . In our experimental in vitro model, antibody trastuzumab, on ligation to its receptor HER2, leads to HER2 down-regulation of total cellular HER2 protein expression in HER2++ ovarian cancer cells SKOV3tA2 (Fig. 1)Citation . An anti-CD71 mAb, known to induce internalization of the TfR (CD71), was used as an irrelevant antibody control. This anti-CD71 mAb did not influence the HER2 protein level of HER2++ ovarian cancer cells coexpressing the TfR.



View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. HER2-overexpressing tumor cells down-regulate total cellular HER2 protein expression after ligation with anti-HER2 mAb trastuzumab. Ovarian cancer cell line SKOV3tA2 expressing the HER2 molecule and the TfR (CD71) was cultured in the absence or presence of either mAb trastuzumab directed against the extracellular domain of HER2 or anti-CD71 mAb. After 2 days, Western blot analysis of SKOV3tA2 cells was performed using mAb c-neu-Ab3 directed against the intracellular domain of HER2. In comparison to untreated SKOV3tA2 cells (Lane a), trastuzumab-treated SKOV3tA2 cells exhibit reduced total cellular HER2 protein expression (Lane b), whereas SKOV3tA2 cells incubated with anti-CD71 mAb did not down-regulate the HER2 molecule (Lane c).

 
It has been shown recently by Klapper et al. (10) that tumor-inhibitory antibodies to HER2 enhances ubiquitination of HER2. Protein tagged to ubiquitin is known to be targeted to the proteasome, which cleaves the protein into small peptides. These peptides are then transported into the endoplasmic reticulum, loaded on MHC class I molecules, and transferred to the cell surface for recognizing CTLs. On the basis of these findings, we next examined whether tumor cells that had down-regulated the HER2 receptor on antibody ligation could become sensitized to lysis by HER2-specific CTLs. We cultured the HER2++ ovarian cancer cell line SKOV3tA2 in the presence of trastuzumab. The trastuzumab-treated SKOV3tA2 cells were then used as target cells for class I-restricted HER2-reactive CTL clones in a cytotoxicity assay. The HER2-specific CTL clones (6) were derived from different donors by in vitro stimulation with autologous DCs transduced retrovirally with HER2. The HER2-specific CTL clone HR-4, generated from an HLA-A2+ patient with HER2++ breast cancer, lysed the HER2++ SKOV3tA2 cells in an HLA-A2-restricted manner (Fig. 2a)Citation . The amount of specific tumor cell lysis correlated with the number of HR-4 CTLs present during the cytotoxicity assay. Pretreatment of SKOV3tA2 cells with trastuzumab resulted in a remarkable increase of tumor cell lysis by CTL clone HR-4. In contrast to nontreated tumor cells, lysis of trastuzumab-treated tumor cells was already detectable at a very low E:T ratio of 1:1. In general, much fewer effector CTLs were needed to lyse equal numbers of antibody-treated tumor cells compared with nontreated tumor cells (e.g., 30% of tumor cell lysis at E:T of 10:1 versus 90:1). Moreover, maximum tumor cell lysis by CTL clone HR-4 was higher (47 versus 26%) and reached at a lower E:T ratio (30:1 versus 90:1), when tumor cells had been incubated with the anti-HER2 antibody. The anti-CD71 mAb capable of inducing TfR internalization did not enhance HR-4-mediated lysis of CD71+ SKOV3tA2. Therefore, it can be excluded that enhanced lysis of tumor cells is a general phenomenon observed after receptor internalization.



View larger version (23K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. HER2-specific CTL clones using different restriction elements lyse HER2-overexpressing tumor cells after incubation with anti-HER2 mAb more efficiently. HLA-A2-restricted CTL clone HR-4 (a) and HLA-A3-restricted CTL clone FS-32 (b), both specific for HER2, were generated by repetitive stimulation with autologous DCs retrovirally transduced with HER2. HER2++ SKOV3tA2 cells expressing the class I molecules HLA-A2 and HLA-A3 were lysed by HLA-A2-restricted CTL clone HR-4 and by HLA-A3-restricted CTL clone FS-32 ({bullet}). Lysis of SKOV3tA2 cells were enhanced when tumor cells were preincubated with anti-HER2 mAb trastuzumab ({blacksquare}). Lytic activity of CTL clones was not altered when SKOV3tA2 cells were treated with an irrelevant mAb recognizing TfR also expressed by SKOV3tA2 ({blacktriangleup}). HER2++ SKBR3 ({circ}) being negative for HLA-A2 and HLA-A3 served as negative control.

 
We next asked whether trastuzumab-treated HER2++ tumor cells were also more efficiently lysed by HER2-specific CTLs using a restriction element other than HLA-A2. CTL clone FS-32 recognizing HER2 in context with HLA-A3 was used for lysing HLA-A3+ SKOV3tA2, which had been cultured in the presence or absence of anti-HER2 and anti-TfR antibody, respectively (Fig. 2b)Citation . Similar to HLA-A2-restricted CTL clone HR-4, the lytic activity of HLA-A3-restricted CTL clone FS-32 was enhanced markedly when tumor cells were preincubated with anti-HER2 mAb trastuzumab. Again, the tumor lysis by CTLs remained unchanged after the incubation of the tumor cells with anti-TfR mAb.

To validate the HER2-specific interaction of trastuzumab and CTLs, we next used CTLs with known peptide specificity as effector cells. CTL line NK-1 (6) recognizing HLA-A2-bound peptide HER2369–377 (4) lysed SKOV3tA2 more efficiently after preincubation with trastuzumab (Fig. 3a)Citation . HLA-A2-restricted CTL clone IR-1 directed against the melanoma-associated peptide melan-A27–35 did not lyse melan-A-negative SKOV3tA2 cells (Fig. 3b)Citation . Culturing SKOV3tA2 cells with trastuzumab did not induce lysis by melan-A-specific CTLs IR-1, indicating that both partners, the antibody and the cytotoxic T cell, need to be HER2 specific to improve killing of HER2++ tumor cells. This tight relationship between trastuzumab-mediated internalization of HER2 and enhanced tumor cell lysis was also observed with HER2-specific CTLs generated from other donors, such as CTL clone PS-D10 (Ref. 6 ; data not shown).



View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Anti-HER2 antibody trastuzumab enhances lysis of HER2++ tumor cells by CTLs recognizing peptide HER2369–377 but not by CTLs specific for peptide melan-A27–35. In a, HLA-A2-restricted CTLs NK-1 recognizes HER2-derived peptide HER2369–377 presented naturally with HLA-A2. T2 cells pulsed with HER2369–377 ({blacktriangleup}) served as positive control, and T2 cells pulsed with the irrelevant peptide derived from the influenza A matrix protein58–66 ({triangleup}) served as negative control. SKOV3tA2 cells naturally expressing peptide HER2369–377 together with HLA-A2 were lysed by CTLs NK-1 ({bullet}). Lysis of SKOV3tA2 cells was augmented after treatment with trastuzumab ({blacksquare}). In b, CTL clone IR-1 lysed T2 cells loaded with melan-A27–35. ({blacktriangledown}) but did not lyse T2 cells pulsed with the irrelevant peptide derived from HIV reverse transcriptase (HIV-pol476–484; {triangledown}). Melan-A-expressing melanoma cell line SKMEL29 ({diamondsuit}) was lysed by CTL clone IR-1. Melan-A-negative SKOV3tA2 cells were not lysed by CTL IR-1, neither with ({bullet}) nor without ({blacksquare}) preincubation with trastuzumab.

 
Several mechanisms have been proposed to account for the antitumor activity of antibodies against HER2. The capacity of a HER2-directed antibody to inhibit the growth of HER2++ tumor cells depends on the ability to down-regulate HER2, subsequently leading to the interruption of signaling pathways (8, 9, 10) . Therefore, one of the main mechanisms responsible for the therapeutic effect of anti-HER2 mAb trastuzumab is thought to be mediated through the inhibition of signal transduction (for review, see Ref. 14 ). However, Stankovski et al. (15) have postulated that inhibition of tumor growth by anti-HER2 mAb is not only because of the blockade of HER2 receptor function but also involves host-tumor interactions. Indeed, Clynes et al. (16) have shown that antibody-dependent cell-mediated cytotoxicity contributes substantially to the antitumor activity of trastuzumab in vivo. In this murine model, growth inhibition of HER2++ tumors was dependent on the engagement of trastuzumab with Fc receptors on myeloid cells, such as monocytes and macrophages. We propose a novel immune mechanism of trastuzumab-mediated tumor killing. Trastuzumab-induced degradation of the HER2 molecule is accompanied probably by the enhanced generation of class I-bound HER2 peptides, and this might lead to a higher susceptibility of HER2-overexpressing tumor cells to CTL-mediated lysis.

The presence of both antibodies and CTLs directed against HER2 in patients with HER2++ tumors (17) suggests that the antitumor activity of HER2-specific antibodies and CTLs might be intertwined. To date, attempts to enhance the preexistent cellular and humoral immunity to HER2 in patients with HER2++ tumors have focused on peptide-based vaccination strategies. In initial clinical studies, the vaccination of women with HER2-overexpressing breast cancer elicited HER2-specific cytotoxic T-cell responses in vivo but have thus far failed to induce tumor regressions (18) . Recent studies have provided evidence that the infusion of antigen-specific T lymphocytes represents an effective modality for the treatment of cancer (12) . Up until now, attempts to treat HER2++ tumors by adoptive transfer of HER2-reactive T cells have not been initiated because of the difficulty of generating autologous CTLs directed against the HER2 antigen. We have succeeded in generating and expanding class I-restricted HER2-specific CTL clones (6, 7) from patients with HER2-overexpressing breast cancer to numbers that allow adoptive T-cell transfer. The synergistic in vitro antitumor activity of trastuzumab and anti-HER2 CTLs described here encourages the transfer of humoral and cellular immunity to patients who fail to completely eradicate cancer by conventional treatment. Braun et al. (19) observed a correlation between HER2 expression on HER2++ micrometastatic tumor cells in bone marrow and poor prognosis. In this context, the relative resistance of HER2++ micrometastatic cells to adjuvant chemotherapy might be successfully overcome by HER2-targeted immunotherapy that is independent of the proliferative status of the target cells.

Because of the expression of HER2 in some normal tissues, it cannot be ruled out that a combination therapy of trastuzumab and anti-HER2 CTLs might induce autoimmune disease. However, because of low-receptor density on normal cells, the binding of trastuzumab could potentially selectively promote class I-restricted presentation of HER2 peptides on HER2++ tumor cells only. Therefore, the combination of trastuzumab and HER2-specific CTLs with low avidity might lead to tumor rejection without damaging normal tissues in vivo (20) . Ongoing studies focus on the toxicity and efficacy of adoptively transferred HER2-specific CTLs with and without trastuzumab in patients with HER2++ breast cancer.


   ACKNOWLEDGMENTS
 
We thank Evelyn Schulz for technical assistance and Claes Öhlén and Wendy Batten for discussion and helpful suggestions.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by grants from the Research Council of Germany (SFB 456), the Wilhelm Sander-Stiftung, and the Deutsche Krebshilfe. Back

2 To whom requests for reprints should be addressed, at Medizinische Klinik, Klinikum rechts der Isar, Technical University of Munich, Ismaningerstr. 22, D-81675 Munich, Germany. Phone:89-4140-6223; Fax: 89-4140-4824; E-mail: helga.bernhard{at}lrz.tum.de Back

3 The abbreviations used are: HER2, human epidermal growth factor receptor 2; HER2++, HER2-overexpressing; DC, dendritic cell; mAb, monoclonal antibody; TfR, transferrin receptor. Back

Received 11/27/01. Accepted 3/ 4/02.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 

  1. Slamon D., Clark G., Wong S., Levin W., Ullrich A., McGuire W. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Wash. DC), 235: 177-182, 1987.[Abstract/Free Full Text]
  2. Schubert U., Antón L. C., Gibbs J., Norbury C. C., Yewdell J. W., Bennink J. R. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature (Lond.), 404: 770-773, 2000.[Medline]
  3. Rock L. K., Goldberg A. L. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol., 17: 739-779, 1999.[Medline]
  4. Fisk B., Blevins T. L., Wharton J. T., Ioannides C. G. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med., 181: 2109-2117, 1995.[Abstract/Free Full Text]
  5. Linehan D. C., Goedegebuure P. S., Peoples G. E., Rogers S. O., Eberlein T. J. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J. Immunol., 155: 4486-4491, 1995.[Abstract]
  6. Meyer zum Büschenfelde C., Nicklisch N., Rose-John S., Peschel C., Bernhard H. Generation of tumor-reactive cytotoxic T lymphocytes against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells. J. Immunol., 165: 4133-4140, 2000.[Abstract/Free Full Text]
  7. Meyer zum Büschenfelde C., Metzger J., Hermann C., Nicklisch N., Peschel C., Bernhard H. The generation of both T killer and T helper cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells. J. Immunol., 167: 1712-1719, 2001.[Abstract/Free Full Text]
  8. Drebin J. A., Link V. C., Stern D. F., Weinberg R. A., Greene M. I. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell, 41: 697-706, 1985.[Medline]
  9. Hurwitz E., Stancovski I., Sela M., Yarden Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc. Natl. Acad. Sci. USA, 92: 3352-3357, 1995.
  10. Klapper L. N., Waterman H., Sela M., Yarden Y. Tumor-inhibitory antibodies to HER-2/erbB-2 may act by recruiting c-cbl and enhancing ubiquitination of HER-2. Cancer Res., 60: 3384-3388, 2000.[Abstract/Free Full Text]
  11. Bernhard H., Lohmann M., Batten W. Y., Metzger J., Löhr H. F., Peschel C., Meyer zum Büschenfelde K-H., Rose-John S. The gp130-stimulating designer cytokine Hyper-IL-6 promotes the expansion of human hematopoietic progenitor cells capable to differentiate into functional dendritic cells. Exp. Hematol., 28: 365-372, 2000.[Medline]
  12. Yee C., Thompson J. A., Roche P., Byrd D. R., Lee P. P., Peipkorn M., Kenyon K., Davis M. M., Riddell S. R., Greenberg P. D. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med., 192: 1637-1643, 2000.[Abstract/Free Full Text]
  13. Carter P., Presta L., Gorman C. M., Ridgeway J. B., Henner D., Wong W., Rowland A. M., Kotts C., Carver M. E., Shepard H. M. Humanization of an anti-p185HER2 monoclonal antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA, 89: 4285-4289, 1992.[Abstract/Free Full Text]
  14. Bange J., Zwick E., Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat. Med., 7: 548-552, 2001.[Medline]
  15. Stankovski I., Hurwitz E., Leitner O., Ullrich A., Yarden Y., Sela M. Mechanistic aspects of the opposing effects of monoclonal antibodies to the erbB2 receptor on tumor growth. Proc. Natl. Acad. Sci. USA, 88: 8691-8695, 1991.[Abstract/Free Full Text]
  16. Clynes R. A., Towers T. L., Presta L. G., Ravetch J. V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med., 6: 443-446, 2000.[Medline]
  17. Disis M. L., Calenoff E., McLaughlin G., Murphy A. E., Chen W., Groner B., Jeschke M., Lydon N., McGlynn E., Livingston R. B., Moe R., Cheever M. A. Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res., 54: 16-20, 1994.[Abstract/Free Full Text]
  18. Knutson K. L., Schiffman K., Disis M. L. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Investig., 107: 477-484, 2001.[Medline]
  19. Braun S., Schlimok G., Heumos I., Schaller G., Riethdorf L., Riethmuller G., Pantel K. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res., 61: 1890-1895, 2001.[Abstract/Free Full Text]
  20. Morgan D. J., Kreuwel H. T. C., Fleck S., Levitsky H. I., Pardoll D. M., Sherman L. A. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol., 160: 643-651, 1998.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Anticancer ResHome page
Y. KAWAGUCHI, K. KONO, Y. MIZUKAMI, K. MIMURA, and H. FUJII
Mechanisms of Escape from Trastuzumab-mediated ADCC in Esophageal Squamous Cell Carcinoma: Relation to Susceptibility to Perforin-granzyme
Anticancer Res, June 1, 2009; 29(6): 2137 - 2146.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. C. Benavides, J. D. Gates, M. G. Carmichael, R. Patel, J. P. Holmes, M. T. Hueman, E. A. Mittendorf, D. Craig, A. Stojadinovic, S. Ponniah, et al.
The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Clin. Cancer Res., April 15, 2009; 15(8): 2895 - 2904.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Stagg, J. Sharkey, S. Pommey, R. Young, K. Takeda, H. Yagita, R. W. Johnstone, and M. J. Smyth
Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response
PNAS, October 21, 2008; 105(42): 16254 - 16259.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. D. Gritzapis, I. F. Voutsas, E. Lekka, N. Tsavaris, I. Missitzis, P. Sotiropoulou, S. Perez, M. Papamichail, and C. N. Baxevanis
Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties
J. Immunol., July 1, 2008; 181(1): 146 - 154.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Conrad, K. Gebhard, H. Kronig, J. Neudorfer, D. H. Busch, C. Peschel, and H. Bernhard
CTLs Directed against HER2 Specifically Cross-React with HER3 and HER4
J. Immunol., June 15, 2008; 180(12): 8135 - 8145.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
V. Goodell, J. Waisman, L. G. Salazar, C. dela Rosa, J. Link, A. L. Coveler, J. S. Childs, P. A. Fintak, D. M. Higgins, and M. L. Disis
Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity
Mol. Cancer Ther., March 1, 2008; 7(3): 449 - 454.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Orlandi, F. M. Venanzi, A. Concetti, H. Yamauchi, S. Tiwari, L. Norton, J. D. Wolchok, A. N. Houghton, and P. D. Gregor
Antibody and CD8+ T Cell Responses against HER2/neu Required for Tumor Eradication after DNA Immunization with a Flt-3 Ligand Fusion Vaccine
Clin. Cancer Res., October 15, 2007; 13(20): 6195 - 6203.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. W.L. Teng, J. A. Westwood, P. K. Darcy, J. Sharkey, M. Tsuji, R. W. Franck, S. A. Porcelli, G. S. Besra, K. Takeda, H. Yagita, et al.
Combined Natural Killer T-Cell Based Immunotherapy Eradicates Established Tumors in Mice
Cancer Res., August 1, 2007; 67(15): 7495 - 7504.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. J. Smyth, Y. Hayakawa, E. Cretney, N. Zerafa, P. Sivakumar, H. Yagita, and K. Takeda
IL-21 Enhances Tumor-Specific CTL Induction by Anti-DR5 Antibody Therapy
J. Immunol., May 15, 2006; 176(10): 6347 - 6355.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
L A Emens, R T Reilly, and E M Jaffee
Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity
Endocr. Relat. Cancer, March 1, 2005; 12(1): 1 - 17.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Kono, E. Sato, H. Naganuma, A. Takahashi, K. Mimura, H. Nukui, and H. Fujii
Trastuzumab (Herceptin) Enhances Class I-Restricted Antigen Presentation Recognized by HER-2/neu-Specific T Cytotoxic Lymphocytes
Clin. Cancer Res., April 1, 2004; 10(7): 2538 - 2544.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
K. Takeda, N. Yamaguchi, H. Akiba, Y. Kojima, Y. Hayakawa, J. E. Tanner, T. J. Sayers, N. Seki, K. Okumura, H. Yagita, et al.
Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy
J. Exp. Med., February 17, 2004; 199(4): 437 - 448.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. L. Knutson, B. Almand, Y. Dang, and M. L. Disis
neu Antigen-Negative Variants Can Be Generated after neu-Specific Antibody Therapy in neu Transgenic Mice
Cancer Res., February 1, 2004; 64(3): 1146 - 1151.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
W. P. Carney, R. Neumann, A. Lipton, K. Leitzel, S. Ali, and C. P. Price
Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer
Clin. Chem., October 1, 2003; 49(10): 1579 - 1598.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. E. Wolpoe, E. R. Lutz, A. M. Ercolini, S. Murata, S. E. Ivie, E. S. Garrett, L. A. Emens, E. M. Jaffee, and R. T. Reilly
HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/neu-Transgenic Mice
J. Immunol., August 15, 2003; 171(4): 2161 - 2169.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Scheffold, M. Kornacker, Y. C. Scheffold, C. H. Contag, and R. S. Negrin
Visualization of Effective Tumor Targeting by CD8+ Natural Killer T Cells Redirected with Bispecific Antibody F(ab')2HER2xCD3
Cancer Res., October 15, 2002; 62(20): 5785 - 5791.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by zum Büschenfelde, C. M.
Right arrow Articles by Bernhard, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by zum Büschenfelde, C. M.
Right arrow Articles by Bernhard, H.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online